BrightSpring Health Services, Inc. - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. BrightSpring Health Services, Inc. is a leading home and community-based healthcare platform operating two primary segments: Pharmacy Solutions and Provider Services. The reporting period reflects the company's strategic shift following the divestiture of its Community Living business, which closed on March 30, 2026, and is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $3,873.1 million | $3,147.7 million | $7,486.9 million | $6,025.8 million |
| Net Income (Continuing Ops) | $86.6 million | $8.5 million | $160.9 million | $17.8 million |
| Operating Income | $130.4 million | $48.6 million | $251.8 million | $99.3 million |
| Adjusted EBITDA | $205.5 million | $142.5 million | $395.3 million | $273.6 million |
| Diluted EPS (Continuing Ops) | $0.39 | $0.04 | $0.73 | $0.09 |
| Cash and Equivalents | $550.4 million | $70.1 million (YTD 2025) | $550.4 million | $70.1 million |
| Total Debt (Gross) | $2,249.3 million | $2,569.7 million | $2,249.3 million | $2,569.7 million |
| Company Leverage Ratio | 2.15x | 2.99x (Dec 31, 2025) | 2.15x | 2.99x |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 23.0% year-over-year in Q2 2026. Pharmacy Solutions revenue grew 22.1% to $3.4 billion, driven by volume growth in Specialty and Infusion Pharmacy. Provider Services revenue grew 30.3% to $466.0 million, significantly aided by the Amedisys and LHC Branches acquisition.
- Profitability Expansion: Operating income surged 168.5% to $130.4 million, and Net Income from continuing operations increased by $78.1 million to $86.6 million. This was driven by gross profit expansion and a reduction in interest expense.
- Divestiture Impact: The sale of the Community Living business generated $810.9 million in cash proceeds and a pre-tax gain of $101.9 million, reported within discontinued operations.
- Debt Refinancing: On May 28, 2026, the company used divestiture proceeds to repay $300.0 million of its Tranche B-5 Term Loan and established a new Tranche B-6 Term Loan of $2,214.9 million at a lower interest rate (SOFR + 2.00%), reducing overall interest costs.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted a "stable reimbursement environment" and continued growth in Senior and Specialty patient populations. The company emphasized its ability to build de novo locations and facilitate integrated care across its pharmacy and provider segments. The refinancing of debt is expected to yield ongoing interest savings.
Risks and Contingencies:
- Regulatory & Reimbursement: Significant reliance on Medicare and Medicaid payments exposes the company to legislative changes, including the Inflation Reduction Act, which has impacted Home and Community Pharmacy revenue.
- Operational Risks: Challenges in recruiting and retaining qualified personnel (nurses, pharmacists) and potential supply chain disruptions for pharmaceutical products.
- Financial Risks: Substantial indebtedness and exposure to variable interest rates, though partially mitigated by $1.5 billion in interest rate swaps.
Investor Verification Checklist
- Verify the sustainability of revenue growth in the Specialty and Infusion Pharmacy segment, which drove the majority of Pharmacy Solutions growth.
- Monitor the impact of the Inflation Reduction Act on Home and Community Pharmacy margins and volume.
- Assess the integration progress and accretion of the Amedisys and LHC Branches acquisition within the Provider Services segment.
- Review the interest rate swap portfolio effectiveness given the company's exposure to variable rates on its $2.2 billion term loan.
- Confirm the trajectory of share repurchases following the concurrent buybacks executed during the June 2026 secondary offering.